Rosuvastatin microcirculatory effects in patients with dyslipidemia and arterial hypertension
Abstract
Aim. To assess microcirculation (MC) dynamics during rosuvastatin therapy in patients with dyslipidemia (DL) and mild to moderate arterial hypertension (AH). Material and methods. The study included 25 patients with total cholesterol (TCH) level >5,0 mmol/l, low-density lipoprotein CH (LDL-CH) level > 3,0 mmol/l, systolic blood pressure (SBP) 140-179 mm Hg, and diastolic BP (DBP) 90-109 mm Hg. For 12 weeks, all participants received rosuvastatin, in constant dose of 10 mg/d. MC was assessed by laser Doppler flowmetry. Results. Rosuvastatin beneficially influenced MC, in various pathological MC types – spastic and hyperemic, according to main MC parameters – MC and capillary blood flow reserve. Regulatory mechanisms’ changes (myogenic amplitude increase) pointed to a decrease in peripheral vascular resistance. Another positive vascular effect of rosuvastatin manifested in significant SBP and DBP reduction, by 8 and 6 mm Hg, respectively. Rosuvastain also demonstrated a substantial lipid-lowering effect. Conclusion. A new statin, rosuvastatin, demonstrated not only substantial lipid-lowering effect, but also beneficial vascular action: it improved MC and reduced BP in patients with DL and mild to moderate AH.
About the Authors
D. V. Nebieridze
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. Moscow
Russian Federation
Russian Federation
G. R. Kulieva
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. Moscow
Russian Federation
Russian Federation
V. A. Vygodin
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. Moscow
Russian Federation
Russian Federation
References
1. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-500.
2. Abbot RD, Wilson PW, Kannel WB, et al. High density lipoprotein total cholesterol screenling and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8: 207-11.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383-9.
4. Faergeman O. Evolution of statin therapy an ongoing story. Eur Heart Suppl 2004; 6(Suppl A): A3-7.
5. Российские рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. ВНОК. Москва 2004.
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 2001; 285: 2486-97.
7. Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average and lower- than average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
8. Аронов Д.М. Плеотропные эффекты статинов. РМЖ 2001; 9(13-14): 578.
9. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99(25): 3227-33.
10. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6.
11. Judd RL. Future Trends in the Pharmacologic Treatment of Hypertension. Auburn University, Graduate Program in Biomedical Sciences, Department of Anatomy, Physiology and Pharmacology 2001.
12. Микроциркуляция в кардиологии. Под редакцией В.И. Маколкина. Москва «Визарт» 2004.
13. Binggeli CMD, Spieker LУ, Corti К, Noll G. Statins Enhanse Postischemic Hyperemia in the Skin Circulation of Hypercholesterolemic Patients. JACC 2003; 42: 71-7.
14. Schuster H, Barter PJ, Stender S, et al. Redactions in Cholesterol Using Rosuvastatin Therapy I study group Effects of switching statins on achievement of lipid goals Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am J Card 2004; 147: 705-13.
15. Susic P, Varagic О, Slama M. Benefical pleotropic vascular effects of rosuvastatin in two hypertensive models. JACC 2003; 1091-7.
16. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: SCORE Project. Eur Heart J 2003; 24: 987-1003.
17. Лазерная допплеровская флоуметрия микроциркуляции крови. Под редакцией А.И. Крупаткина, В.В. Сидорова. Рук-во для врачей. Медицина 2005.
18. Небиеридзе Д.В., Тваладзе И.А., Выгодин В.А., и др. Изучение гипотензивного эффекта правастатина у больных мягкой артериальной гипертонией и гиперхолестеринемией. Кардиоваск тер профил 2002; 1: 22-6.
Review
For citations:
Nebieridze D.V., Kulieva G.R., Vygodin V.A. Rosuvastatin microcirculatory effects in patients with dyslipidemia and arterial hypertension. Cardiovascular Therapy and Prevention. 2006;5(4):41-45. (In Russ.)
Views:
451
Email this article 
